Tagrisso alone did not produce as much good result then TAGRISSO (osimertinib) plus chemotherapy did for patients with stage locally advanced or metastatic non-small cell lung cancer (NSCLC) advanced EGFR mutations in phase 3 FLAURA2 trial at AstraZeneca.
According to AstraZeneca press release “the findings of the FLAURA2 trial showed that adding Tagrisso to chemotherapy significantly improved progression-free survival, or the length of time a cancer patient lives with disease without worsening, rather than chemotherapy alone.”
“As the global standard of care for EGFR-mutated non-small cell lung cancer, osimertinib monotherapy has transformed the treatment landscape allowing many patients the opportunity to achieve improved survival. FLAURA2 provides compelling evidence that the addition of chemotherapy to osimertinib can provide a new option for patients and clinicians that further improves outcomes compared to osimertinib alone and as such, can further delay treatment resistance and disease progression.” said by Pasi A. Jänne, MD, PhD, medical oncologist at Dana-Farber Cancer Institute and principal investigator for the FLAURA2 trial.
Susan Galbraith – Executive Vice President and Oncology R&D at AstraZeneca said “These significant FLAURA2 results show TAGRISSO has the potential to offer patients in the first-line setting a new treatment option that can extend the time they live without their disease progressing. This meaningfully builds on successive trials which have demonstrated improved clinical benefit with TAGRISSO in patients with EGFR-mutated lung cancer.”
Several factors including overall survival, progression-free survival, objective response rate and duration of response, among others were monitored throughout the trial. According to the press release the data will we presented at a forthcoming medical meeting and shared with global health authorities.
Each year 30–40% of patients in Asia are diagnosed with EGFRm NSCLC while in the US and Europe 80–85% of patients are diagnosed with NSCLC and approximately 70% are diagnosed with advanced NSCLC. Since NSCLC is the most common form of lung cancer, more research and better results are milestones for effective treatment.
The information shared in this blog is for educational purposes only and is certainly not a substitute for medical advice. Please consult your healthcare practitioner for any medical needs.
Subscribe to our newsletter or follow us on Facebook or Twitter today and never miss out an update!